Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RANA R MCKAY

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1306013610
CMS profile
541869
Location
SAN DIEGO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$88,428.18

78 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RANA R MCKAY

NPI 1306013610 · CMS profile ID 541869

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

SAN DIEGO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1306013610?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RANA R MCKAY, NPI 1306013610, CMS profile ID 541869. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1306013610?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). RANA R MCKAY, NPI 1306013610, CMS profile ID 541869. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1306013610?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
RANA R MCKAY, NPI 1306013610, CMS profile ID 541869, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1306013610?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

78 matching records · $88,428.18 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 78 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–78 of 78.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $39.4405/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238006894 CMS
Merck Sharp & Dohme LLC $147.2805/14/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238008812 CMS
Novartis Pharmaceuticals Corporation $1,062.5004/30/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1200657472 CMS
Bayer Healthcare Pharmaceuticals Inc. $2,280.0004/25/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1225647960 CMS
Merck Sharp & Dohme LLC $1,280.0004/21/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1238036598 CMS
Merck Sharp & Dohme LLC $34.4104/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238064570 CMS
Merck Sharp & Dohme LLC $7,680.0004/14/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1237999330 CMS
Merck Sharp & Dohme LLC $15.0004/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238000476 CMS
Merck Sharp & Dohme LLC $35.0004/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238003982 CMS
Merck Sharp & Dohme LLC $85.0004/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238002902 CMS
Merck Sharp & Dohme LLC $372.4204/08/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238036032 CMS
Merck Sharp & Dohme LLC $205.2104/08/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238036600 CMS
Merck Sharp & Dohme LLC $113.4104/08/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238037598 CMS
Merck Sharp & Dohme LLC $156.1504/08/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238040417 CMS
Merck Sharp & Dohme LLC $1,220.0004/02/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1237995654 CMS
Exelixis Inc. $24.5603/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218801879 CMS
AstraZeneca UK Limited $4,110.0003/20/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1202987276 CMS
PFIZER INC. $1,460.0002/27/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1231375670 CMS
AstraZeneca UK Limited $2,460.0002/14/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1202987162 CMS
Exelixis Inc. $133.6402/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218801877 CMS
Telix Pharmaceuticals $53.8202/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189636115 CMS
Daiichi Sankyo Inc. $2,437.5002/13/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1197028999 CMS
PFIZER INC. $161.2202/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231604299 CMS
AstraZeneca Pharmaceuticals LP $342.5001/22/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1207010830 CMS
Exelixis Inc. $9.2601/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218801875 CMS
AstraZeneca Pharmaceuticals LP $1.8001/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206576183 CMS
AstraZeneca Pharmaceuticals LP $22.9301/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206133520 CMS
Merck Sharp & Dohme LLC $12.3701/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238382620 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $23,207.51 30
PY2020 $53,890.48 32
PY2021 $70,069.22 39
PY2022 $66,950.66 56
PY2023 $86,926.59 69
PY2024 $140,620.16 75
PY2025 $88,428.18 78

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $13,238.30 9
PY2025 Principal investigator $4,323,458.05 242
PY2024 Recipient $3,352.89 4
PY2024 Principal investigator $3,527,490.91 155
PY2023 Principal investigator $2,840,835.77 138
PY2022 Recipient $1,449.34 5
PY2022 Principal investigator $1,325,471.04 117
PY2021 Principal investigator $997,595.76 89
PY2020 Principal investigator $1,293,611.44 109
PY2019 Principal investigator $444,496.16 30

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

251 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $8,261.78 12/31/2025 Non-covered Recipient Entity
Moores Cancer Center
A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC IDeate-Prostate01 No dispute reported 06/30/2026 1232922368
Principal investigator 1 Merck Sharp & Dohme LLC $8,433.80 12/31/2025 Non-covered Recipient Entity
University of California San Diego Moores Cancer Center
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 1232931462
Principal investigator 1 Merck Sharp & Dohme LLC $10,951.29 12/31/2025 Non-covered Recipient Entity
UC San Diego
An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Belzutifan MK-6482 and Lenvatinib MK-7902, or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First No dispute reported 06/30/2026 1232934812
Principal investigator 1 Merck Sharp & Dohme LLC $317,789.36 12/31/2025 Non-covered Recipient Entity
UC San Diego
An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Belzutifan MK-6482 and Lenvatinib MK-7902, or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First No dispute reported 06/30/2026 1232934814
Principal investigator 1 Merck Sharp & Dohme LLC $11,014.20 12/31/2025 Non-covered Recipient Entity
Moores Cancer Center-Clinical Trials Office- Genitourinary
A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Neph No dispute reported 06/30/2026 1232934945
Principal investigator 1 Novartis Pharmaceuticals Corporation $857.93 12/31/2025 Non-covered Recipient Entity
UC SAN DIEGO HEALTH BLOOD DRAWING LAB
A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1190313911
Principal investigator 1 Novartis Pharmaceuticals Corporation $857.93 12/31/2025 Non-covered Recipient Entity
UC SAN DIEGO HEALTH BLOOD DRAWING LAB
A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1190313913
Principal investigator 1 Janssen Research & Development, LLC $11,080.00 12/29/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFO
A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer No dispute reported 06/30/2026 1175443383
Principal investigator 1 Merck Sharp & Dohme LLC $215,211.68 12/10/2025 Non-covered Recipient Entity
Moores Cancer Center-Clinical Trials Office- Genitourinary
A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Neph No dispute reported 06/30/2026 1232934943
Principal investigator 1 Exelixis Inc. $22,750.00 12/08/2025 Non-covered Recipient Entity
Hoosier Cancer Research Network, Inc.
A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer No dispute reported 06/30/2026 1222380864
Principal investigator 1 Janssen Research & Development, LLC $8,487.00 12/04/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFO
A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer No dispute reported 06/30/2026 1175443210
Principal investigator 1 Janssen Research & Development, LLC $2,336.00 12/04/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFO
A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer No dispute reported 06/30/2026 1175443214
Principal investigator 1 Janssen Research & Development, LLC $2,950.00 12/01/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFO
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175443340
Principal investigator 1 Janssen Research & Development, LLC $15,475.00 11/28/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFO
A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer No dispute reported 06/30/2026 1175443222
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,000.00 11/27/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409558
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $13.50 11/27/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409572
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $65.12 11/27/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409584
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,819.61 11/27/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409588
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $137.90 11/27/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409592
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,592.87 11/27/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409606
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $270.00 11/27/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409608
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,819.61 11/27/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409610
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $270.00 11/27/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409614
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $65.12 11/27/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409632
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,457.80 11/27/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409636
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,457.80 11/27/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409644
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $57.50 11/27/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409646
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,592.87 11/27/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409664
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $57.50 11/27/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409672
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $57.50 11/27/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409674
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,000.00 11/27/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409682
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $111.09 11/27/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409704
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,000.00 11/27/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409726
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $274.05 11/27/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409728
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $182.60 11/27/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409736
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,819.61 11/27/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409744
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $57.50 11/27/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409770
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,819.61 11/27/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409778
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $44.55 11/27/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409798
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $25.65 11/27/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409800
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,457.80 11/27/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409826
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,592.87 11/27/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409832
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,592.87 11/27/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409844
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,000.00 11/27/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409848
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $71.51 11/27/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409860
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $270.00 11/27/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409862
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $21,000.00 11/27/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409876
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,457.80 11/27/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409886
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $270.00 11/27/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409888
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $41.85 11/27/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409892
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $187.70 11/27/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409896
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,183.00 11/21/2025 Non-covered Recipient Entity
University Of California San Diego
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge No dispute reported 06/30/2026 1235992687
Principal investigator 1 Exelixis Inc. $18,200.00 11/17/2025 Non-covered Recipient Entity
Hoosier Cancer Research Network, Inc.
A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer No dispute reported 06/30/2026 1222380868
Principal investigator 1 Exelixis Inc. $4,550.00 11/17/2025 Non-covered Recipient Entity
Hoosier Cancer Research Network, Inc.
A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer No dispute reported 06/30/2026 1222380872
Principal investigator 1 Exelixis Inc. $11,082.50 11/17/2025 Non-covered Recipient Entity
Hoosier Cancer Research Network, Inc.
A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer No dispute reported 06/30/2026 1222380874
Principal investigator 1 Exelixis Inc. $107,961.00 11/17/2025 Non-covered Recipient Entity
Hoosier Cancer Research Network, Inc.
A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer No dispute reported 06/30/2026 1222380882
Recipient PFIZER INC. $1,400.00 11/06/2025 Covered Recipient Physician ENFORTUMAB VEDOTIN CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727881
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $111,221.22 11/05/2025 Non-covered Recipient Entity
Alliance For Clinical Trials In Oncology Foundation
Global Clinical Study Agreement Xofigo A031801 A Phase I II Randomized Trial of Radium 223 and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis RadiCal Claudia No dispute reported 06/30/2026 1225408922
Principal investigator 1 Merck Sharp & Dohme LLC $797,490.46 11/05/2025 Non-covered Recipient Entity
UC San Diego
An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Belzutifan MK-6482 and Lenvatinib MK-7902, or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First No dispute reported 06/30/2026 1232934810
Principal investigator 1 Sumitomo Pharma America, Inc. $1,909.14 11/05/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CA SAN DIEGO
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176654842
Principal investigator 1 Sumitomo Pharma America, Inc. $969.57 11/05/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CA SAN DIEGO
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176655056
Principal investigator 1 Janssen Research & Development, LLC $16,550.00 11/03/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CEN
MultiModality Therapeutic Approaches to Eliminate Disease in the Prostate and, Separately, in Metastatic Sites No dispute reported 06/30/2026 1175308654
Principal investigator 1 Exelixis Inc. $3,900.00 10/31/2025 Non-covered Recipient Entity
The Regents of the University of California at San Diego
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222385402
Principal investigator 1 Exelixis Inc. $36,036.00 10/31/2025 Non-covered Recipient Entity
The Regents of the University of California at San Diego
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222385404
Principal investigator 1 Exelixis Inc. $780.00 10/31/2025 Non-covered Recipient Entity
The Regents of the University of California at San Diego
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222385406
Principal investigator 1 Exelixis Inc. $2,340.00 10/31/2025 Non-covered Recipient Entity
The Regents of the University of California at San Diego
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222385408
Principal investigator 1 Janssen Research & Development, LLC $332.50 10/21/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFO
A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer No dispute reported 06/30/2026 1175443422
Principal investigator 1 Exelixis Inc. $9,100.00 10/20/2025 Non-covered Recipient Entity
Hoosier Cancer Research Network, Inc.
A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer No dispute reported 06/30/2026 1222380862
Principal investigator 1 Exelixis Inc. $16,111.50 10/20/2025 Non-covered Recipient Entity
The Regents of the University of California at San Diego
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma No dispute reported 06/30/2026 1222385434
Recipient PFIZER INC. $940.00 10/18/2025 Covered Recipient Physician ENFORTUMAB VEDOTIN CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727727
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,351.41 10/15/2025 Non-covered Recipient Entity
UC SAN DIEGO HEALTH BLOOD DRAWING LAB
A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1190306093
Principal investigator 1 Exelixis Inc. $3,965.00 10/13/2025 Non-covered Recipient Entity
Hoosier Cancer Research Network, Inc.
A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer No dispute reported 06/30/2026 1222380860
Principal investigator 1 Exelixis Inc. $12,663.34 10/13/2025 Non-covered Recipient Entity
Hoosier Cancer Research Network, Inc.
A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer No dispute reported 06/30/2026 1222380866
Principal investigator 1 Exelixis Inc. $107,961.00 10/13/2025 Non-covered Recipient Entity
Hoosier Cancer Research Network, Inc.
A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer No dispute reported 06/30/2026 1222380870
Principal investigator 1 Exelixis Inc. $7,550.00 10/13/2025 Non-covered Recipient Entity
Hoosier Cancer Research Network, Inc.
A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer No dispute reported 06/30/2026 1222380878
Principal investigator 1 Exelixis Inc. $9,100.00 10/13/2025 Non-covered Recipient Entity
Hoosier Cancer Research Network, Inc.
A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer No dispute reported 06/30/2026 1222380880
Principal investigator 1 Exelixis Inc. $107,961.00 10/06/2025 Non-covered Recipient Entity
Hoosier Cancer Research Network, Inc.
A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer No dispute reported 06/30/2026 1222380876
Principal investigator 1 Janssen Research & Development, LLC $33,216.67 10/06/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CEN
MultiModality Therapeutic Approaches to Eliminate Disease in the Prostate and, Separately, in Metastatic Sites No dispute reported 06/30/2026 1175309395
Principal investigator 1 Celgene Corporation $86,337.00 09/30/2025 Non-covered Recipient Entity
The Regents Of The University Of California
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge No dispute reported 06/30/2026 1222306465
Principal investigator 1 Aveo Pharmaceuticals, Inc. $122.58 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911933
Principal investigator 1 Aveo Pharmaceuticals, Inc. $107.91 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911935
Principal investigator 1 Aveo Pharmaceuticals, Inc. $107.91 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911937
Principal investigator 1 Aveo Pharmaceuticals, Inc. $84.08 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911939
Principal investigator 1 Aveo Pharmaceuticals, Inc. $148.36 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911965
Principal investigator 1 Aveo Pharmaceuticals, Inc. $18.39 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911967
Principal investigator 1 Aveo Pharmaceuticals, Inc. $18.39 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911969
Principal investigator 1 Aveo Pharmaceuticals, Inc. $84.08 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911971
Principal investigator 1 Aveo Pharmaceuticals, Inc. $84.08 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911973
Principal investigator 1 Aveo Pharmaceuticals, Inc. $106.08 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911975
Principal investigator 1 Aveo Pharmaceuticals, Inc. $92.78 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911977
Principal investigator 1 Aveo Pharmaceuticals, Inc. $122.58 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911979
Principal investigator 1 Aveo Pharmaceuticals, Inc. $84.08 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911981
Principal investigator 1 Aveo Pharmaceuticals, Inc. $18.39 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911983
Principal investigator 1 Aveo Pharmaceuticals, Inc. $106.55 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911985
Principal investigator 1 Aveo Pharmaceuticals, Inc. $106.55 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911987
Principal investigator 1 Aveo Pharmaceuticals, Inc. $84.08 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911989
Principal investigator 1 Aveo Pharmaceuticals, Inc. $92.78 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911991
Principal investigator 1 Aveo Pharmaceuticals, Inc. $106.08 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911993
Principal investigator 1 Aveo Pharmaceuticals, Inc. $92.78 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911995
Principal investigator 1 Aveo Pharmaceuticals, Inc. $148.36 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912001
Principal investigator 1 Aveo Pharmaceuticals, Inc. $18.39 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912003
Principal investigator 1 Aveo Pharmaceuticals, Inc. $106.08 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912005
Principal investigator 1 Aveo Pharmaceuticals, Inc. $106.55 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912007
Principal investigator 1 Aveo Pharmaceuticals, Inc. $18.39 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912009
Principal investigator 1 Aveo Pharmaceuticals, Inc. $85.76 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912011
Principal investigator 1 Aveo Pharmaceuticals, Inc. $92.78 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912013
Principal investigator 1 Aveo Pharmaceuticals, Inc. $106.55 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912015
Principal investigator 1 Aveo Pharmaceuticals, Inc. $84.08 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912017
Principal investigator 1 Aveo Pharmaceuticals, Inc. $92.78 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912019
Principal investigator 1 Aveo Pharmaceuticals, Inc. $78.43 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912021
Principal investigator 1 Aveo Pharmaceuticals, Inc. $92.78 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912023
Principal investigator 1 Aveo Pharmaceuticals, Inc. $78.43 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912025
Principal investigator 1 Aveo Pharmaceuticals, Inc. $18.39 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912027
Principal investigator 1 Aveo Pharmaceuticals, Inc. $78.43 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912029
Principal investigator 1 Aveo Pharmaceuticals, Inc. $18.39 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912031
Principal investigator 1 Aveo Pharmaceuticals, Inc. $18.39 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912033
Principal investigator 1 Aveo Pharmaceuticals, Inc. $18.39 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912035
Principal investigator 1 Aveo Pharmaceuticals, Inc. $92.78 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912037
Principal investigator 1 Aveo Pharmaceuticals, Inc. $92.78 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912039
Principal investigator 1 Aveo Pharmaceuticals, Inc. $107.91 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912041
Principal investigator 1 Aveo Pharmaceuticals, Inc. $148.36 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912043
Principal investigator 1 Aveo Pharmaceuticals, Inc. $85.76 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912045
Principal investigator 1 Aveo Pharmaceuticals, Inc. $92.78 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912047
Principal investigator 1 Aveo Pharmaceuticals, Inc. $18.39 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912049
Principal investigator 1 Aveo Pharmaceuticals, Inc. $18.39 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912065
Principal investigator 1 Aveo Pharmaceuticals, Inc. $18.39 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912067
Principal investigator 1 Aveo Pharmaceuticals, Inc. $84.08 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912069
Principal investigator 1 Aveo Pharmaceuticals, Inc. $122.58 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912071
Principal investigator 1 Aveo Pharmaceuticals, Inc. $18.39 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912073
Principal investigator 1 Aveo Pharmaceuticals, Inc. $84.08 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912075
Principal investigator 1 Aveo Pharmaceuticals, Inc. $18.39 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912077
Principal investigator 1 Aveo Pharmaceuticals, Inc. $84.08 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912079
Principal investigator 1 Aveo Pharmaceuticals, Inc. $85.76 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912081
Principal investigator 1 Aveo Pharmaceuticals, Inc. $92.78 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912083
Principal investigator 1 Aveo Pharmaceuticals, Inc. $92.78 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912085
Principal investigator 1 Aveo Pharmaceuticals, Inc. $148.36 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912087
Principal investigator 1 Aveo Pharmaceuticals, Inc. $84.08 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912089
Principal investigator 1 Aveo Pharmaceuticals, Inc. $85.76 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912091
Principal investigator 1 Aveo Pharmaceuticals, Inc. $107.91 09/15/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912095
Principal investigator 1 Exelixis Inc. $2,976.00 09/11/2025 Non-covered Recipient Entity
The Regents of the University of California at San Diego
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222385378
Principal investigator 1 Exelixis Inc. $3,165.40 09/11/2025 Non-covered Recipient Entity
The Regents of the University of California at San Diego
A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222385432
Principal investigator 1 Exelixis Inc. $31,850.00 09/08/2025 Non-covered Recipient Entity
Hoosier Cancer Research Network, Inc.
A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer No dispute reported 06/30/2026 1222380852
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,507.70 09/04/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912093
Principal investigator 1 Janssen Research & Development, LLC $72,006.60 09/04/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFO RNIA AT SAN DIEGO
A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer No dispute reported 06/30/2026 1175443258
Principal investigator 1 Merck Sharp & Dohme LLC $215,844.48 08/31/2025 Non-covered Recipient Entity
Moores Cancer Center-Clinical Trials Office- Genitourinary
A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Neph No dispute reported 06/30/2026 1232934947
Principal investigator 1 Aveo Pharmaceuticals, Inc. $594.56 08/28/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912051
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,772.94 08/28/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912053
Principal investigator 1 Aveo Pharmaceuticals, Inc. $594.56 08/28/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912055
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,772.94 08/28/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912057
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,772.94 08/28/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912059
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,772.94 08/28/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912061
Principal investigator 1 Aveo Pharmaceuticals, Inc. $594.56 08/28/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199912063
Principal investigator 1 Janssen Research & Development, LLC $1,378.00 08/25/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFO RNIA AT SAN DIEGO
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175443473
Principal investigator 1 Exelixis Inc. $992.00 08/18/2025 Non-covered Recipient Entity
The Regents of the University of California at San Diego
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222385380
Principal investigator 1 Exelixis Inc. $1,859.53 08/18/2025 Non-covered Recipient Entity
The Regents of the University of California at San Diego
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222385382
Principal investigator 1 Exelixis Inc. $992.00 08/06/2025 Non-covered Recipient Entity
The Regents of the University of California at San Diego
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222385384
Recipient Novartis Pharmaceuticals Corporation $237.67 08/05/2025 Covered Recipient Physician Research Publication/ Writing Support No dispute reported 06/30/2026 1190293029
Principal investigator 1 Sumitomo Pharma America, Inc. $15,368.69 08/01/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CA SAN DIEGO
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176641756
Principal investigator 1 Sumitomo Pharma America, Inc. $532.00 08/01/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CA SAN DIEGO
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176641759
Principal investigator 1 Janssen Research & Development, LLC $1,902.00 07/24/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFO RNIA AT SAN DIEGO
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175443336
Principal investigator 1 Exelixis Inc. $107,961.00 07/21/2025 Non-covered Recipient Entity
Hoosier Cancer Research Network, Inc.
A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer No dispute reported 06/30/2026 1222380856
Principal investigator 1 AstraZeneca Pharmaceuticals LP $434,001.50 07/14/2025 Non-covered Recipient Entity
HOOSIER CANCER RESEARCH NETWORK
A Phase 2 Study of Neoadjuvant PARP Inhibition followed by Radical Prostatectomy in Patients with Unfavorable Intermediate-Risk or High-Risk Prostate Cancer with Germline Homologous Recombination Repair Gene Alterations (NePtune) No dispute reported 06/30/2026 1185549159
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $976.59 07/14/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409116
Principal investigator 1 Exelixis Inc. $5,720.00 07/14/2025 Non-covered Recipient Entity
Hoosier Cancer Research Network, Inc.
A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer No dispute reported 06/30/2026 1222380850
Principal investigator 1 Exelixis Inc. $9,100.00 07/14/2025 Non-covered Recipient Entity
Hoosier Cancer Research Network, Inc.
A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer No dispute reported 06/30/2026 1222380854
Principal investigator 1 Exelixis Inc. $10,100.00 07/14/2025 Non-covered Recipient Entity
Hoosier Cancer Research Network, Inc.
A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer No dispute reported 06/30/2026 1222380858
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $41.85 06/25/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407848
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $87.74 06/25/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407854
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $67.68 06/25/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407900
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $65.12 06/25/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407908
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $337.50 06/25/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407910
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $71.51 06/25/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407928
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $65.12 06/25/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408052
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $74.25 06/25/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408080
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $67.50 06/25/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408120
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $178.77 06/25/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408152
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $167.27 06/25/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408332
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $274.05 06/25/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408334
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $87.75 06/25/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408390
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $32.56 06/25/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408400
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,000.00 06/25/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408416
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $111.09 06/25/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408436
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $13.50 06/25/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408456
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $137.90 06/25/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408494
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $187.70 06/25/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408518
Principal investigator 1 Janssen Research & Development, LLC $1,048.00 06/20/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFO RNIA AT SAN DIEGO
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175443307
Principal investigator 1 Janssen Research & Development, LLC $2,620.00 06/20/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFO RNIA AT SAN DIEGO
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175443324
Principal investigator 1 Janssen Research & Development, LLC $8,780.00 06/20/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFO RNIA AT SAN DIEGO
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175443407
Principal investigator 1 Aveo Pharmaceuticals, Inc. $988.00 06/16/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911961
Principal investigator 1 Exelixis Inc. $13,650.00 06/09/2025 Non-covered Recipient Entity
Hoosier Cancer Research Network, Inc.
A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer No dispute reported 06/30/2026 1222380846
Recipient Novartis Pharmaceuticals Corporation $2,710.63 06/02/2025 Covered Recipient Physician Research Publication/Writing Support No dispute reported 06/30/2026 1190292207
Principal investigator 1 Aveo Pharmaceuticals, Inc. $594.56 05/28/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911997
Principal investigator 1 Exelixis Inc. $40,950.00 05/27/2025 Non-covered Recipient Entity
Hoosier Cancer Research Network, Inc.
A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer No dispute reported 06/30/2026 1222380848
Principal investigator 1 Aveo Pharmaceuticals, Inc. $3,900.00 05/21/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911957
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,170.00 05/21/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911959
Principal investigator 1 Aveo Pharmaceuticals, Inc. $715.00 05/21/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911963
Principal investigator 1 Aveo Pharmaceuticals, Inc. $195.00 05/21/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911999
Principal investigator 1 AstraZeneca Pharmaceuticals LP $346,250.00 05/20/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
A Pilot Study to Improve Germline Testing in At Risk Patients with Prostate No dispute reported 06/30/2026 1185549163
Recipient PFIZER INC. $330.00 05/13/2025 Covered Recipient Physician ENFORTUMAB VEDOTIN CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228759894
Principal investigator 1 Janssen Research & Development, LLC $1,048.00 04/28/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFO RNIA
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175443561
Principal investigator 1 Exelixis Inc. $10,362.60 04/23/2025 Non-covered Recipient Entity
The Regents of the University of California at San Diego
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma No dispute reported 06/30/2026 1222385430
Recipient PFIZER INC. $1,900.00 04/22/2025 Covered Recipient Physician RELUGOLIX CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228752120
Recipient PFIZER INC. $1,900.00 04/22/2025 Covered Recipient Physician RELUGOLIX CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228771425
Principal investigator 1 Merck Sharp & Dohme LLC $35,787.40 04/21/2025 Non-covered Recipient Entity
University of California San Diego Moores Cancer Center
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 1232931222
Principal investigator 1 Exelixis Inc. $107,961.00 04/14/2025 Non-covered Recipient Entity
Hoosier Cancer Research Network, Inc.
A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer No dispute reported 06/30/2026 1222380844
Recipient PFIZER INC. $3,200.00 04/10/2025 Covered Recipient Physician ENFORTUMAB VEDOTIN CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228769835
Principal investigator 1 AstraZeneca Pharmaceuticals LP $156,686.68 03/31/2025 Non-covered Recipient Entity
HOOSIER CANCER RESEARCH NETWORK
A Phase 2 Study of Neoadjuvant PARP Inhibition followed by Radical Prostatectomy in Patients with Unfavorable Intermediate-Risk or High-Risk Prostate Cancer with Germline Homologous Recombination Repair Gene Alterations (NePtune) No dispute reported 06/30/2026 1185549161
Principal investigator 1 Janssen Research & Development, LLC $1,048.00 03/27/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFO RNIA
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175443498
Principal investigator 1 Aveo Pharmaceuticals, Inc. $436.80 03/25/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911919
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,368.00 03/25/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911921
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,170.00 03/25/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911923
Principal investigator 1 Aveo Pharmaceuticals, Inc. $867.10 03/25/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911925
Principal investigator 1 Aveo Pharmaceuticals, Inc. $10,816.00 03/25/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911927
Principal investigator 1 Aveo Pharmaceuticals, Inc. $49.40 03/25/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911929
Principal investigator 1 Aveo Pharmaceuticals, Inc. $429.00 03/25/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911931
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,139.08 03/24/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225403651
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,321.68 03/24/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225405608
Principal investigator 1 Exelixis Inc. $9,100.00 03/17/2025 Non-covered Recipient Entity
Hoosier Cancer Research Network, Inc.
A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer No dispute reported 06/30/2026 1222380836
Principal investigator 1 Exelixis Inc. $4,485.00 03/17/2025 Non-covered Recipient Entity
Hoosier Cancer Research Network, Inc.
A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer No dispute reported 06/30/2026 1222380840
Principal investigator 1 Exelixis Inc. $43,693.00 03/17/2025 Non-covered Recipient Entity
Hoosier Cancer Research Network, Inc.
A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer No dispute reported 06/30/2026 1222380842
Principal investigator 1 Exelixis Inc. $3,120.00 03/14/2025 Non-covered Recipient Entity
The Regents of the University of California at San Diego
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma No dispute reported 06/30/2026 1222385412
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $23,545.00 03/03/2025 Non-covered Recipient Entity
University Of California San Diego
A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer (CANOPY) No dispute reported 06/30/2026 1235992685
Principal investigator 1 Exelixis Inc. $5,200.00 03/03/2025 Non-covered Recipient Entity
The Regents of the University of California at San Diego
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma No dispute reported 06/30/2026 1222385416
Principal investigator 1 Exelixis Inc. $8,910.00 03/03/2025 Non-covered Recipient Entity
The Regents of the University of California at San Diego
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma No dispute reported 06/30/2026 1222385418
Principal investigator 1 Aveo Pharmaceuticals, Inc. $594.56 02/27/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911915
Principal investigator 1 Aveo Pharmaceuticals, Inc. $594.56 02/27/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911917
Principal investigator 1 Janssen Research & Development, LLC $16,250.00 02/17/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFO RNIA
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175443602
Principal investigator 1 Exelixis Inc. $195.00 02/14/2025 Non-covered Recipient Entity
The Regents of the University of California at San Diego
A Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with High-Risk, Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1222385420
Principal investigator 1 Exelixis Inc. $1,950.00 02/14/2025 Non-covered Recipient Entity
The Regents of the University of California at San Diego
A Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with High-Risk, Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1222385422
Principal investigator 1 Exelixis Inc. $3,900.00 02/14/2025 Non-covered Recipient Entity
The Regents of the University of California at San Diego
A Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with High-Risk, Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1222385424
Principal investigator 1 Exelixis Inc. $715.00 02/14/2025 Non-covered Recipient Entity
The Regents of the University of California at San Diego
A Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with High-Risk, Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1222385426
Principal investigator 1 Exelixis Inc. $1,170.00 02/14/2025 Non-covered Recipient Entity
The Regents of the University of California at San Diego
A Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with High-Risk, Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1222385428
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $105,584.40 02/05/2025 Non-covered Recipient Entity
Alliance For Clinical Trials In Oncology Foundation
Global Clinical Study Agreement Xofigo A031801 A Phase I II Randomized Trial of Radium 223 and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis RadiCal Claudia No dispute reported 06/30/2026 1225402187
Principal investigator 1 Exelixis Inc. $1,984.00 02/05/2025 Non-covered Recipient Entity
The Regents of the University of California at San Diego
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222385354
Principal investigator 1 Janssen Research & Development, LLC $3,668.00 02/03/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFO RNIA
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175443584
Recipient PFIZER INC. $620.00 02/03/2025 Covered Recipient Physician RELUGOLIX CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228753947
Principal investigator 1 Aveo Pharmaceuticals, Inc. $594.56 01/27/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911955
Principal investigator 1 Exelixis Inc. $2,600.00 01/24/2025 Non-covered Recipient Entity
The Regents of the University of California at San Diego
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma No dispute reported 06/30/2026 1222385410
Principal investigator 1 Exelixis Inc. $3,120.00 01/24/2025 Non-covered Recipient Entity
The Regents of the University of California at San Diego
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma No dispute reported 06/30/2026 1222385414
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $338.35 01/21/2025 Non-covered Recipient Entity
UC San Diego Health La Jolla
A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus Bempegaldesleukin (NKTR214), Versus Nivolumab Alone Versus Standard of Care in Participants With MuscleInvasive Bladder Cancer (MIBC) Who Are Cisplatin Ineligible No dispute reported 06/30/2026 1235992809
Principal investigator 1 Eli Lilly and Company $53,259.00 01/21/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
CYCLONE 3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ABEMACICLIB IN COMBINATION WITH ABIRATERONE PLUS PREDNISONE IN MEN WITH HIGH-RISK METASTATIC HORMONE-SENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1187888282
Principal investigator 1 Exelixis Inc. $4,894.50 01/13/2025 Non-covered Recipient Entity
Hoosier Cancer Research Network, Inc.
A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer No dispute reported 06/30/2026 1222380832
Principal investigator 1 Exelixis Inc. $9,100.00 01/13/2025 Non-covered Recipient Entity
Hoosier Cancer Research Network, Inc.
A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer No dispute reported 06/30/2026 1222380834
Principal investigator 1 Exelixis Inc. $81,900.00 01/13/2025 Non-covered Recipient Entity
Hoosier Cancer Research Network, Inc.
A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer No dispute reported 06/30/2026 1222380838
Principal investigator 1 Aveo Pharmaceuticals, Inc. $780.00 01/08/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911941
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,405.00 01/08/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911943
Principal investigator 1 Aveo Pharmaceuticals, Inc. $10,920.00 01/08/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911945
Principal investigator 1 Aveo Pharmaceuticals, Inc. $3,900.00 01/08/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911947
Principal investigator 1 Aveo Pharmaceuticals, Inc. $10,400.00 01/08/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911949
Principal investigator 1 Aveo Pharmaceuticals, Inc. $594.56 01/08/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911951
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,340.00 01/08/2025 Non-covered Recipient Entity
The Regents of the University of California
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911953